Evidence map›Paper›PMID 37620940›Full record

ArticleWorld journal of surgical oncology2023

Risk factors for early recurrence in patients with pancreatic ductal adenocarcinoma who underwent curative resection.

Masaaki Murakawa, Shinnosuke Kawahara, Daishi Takahashi, Yuto Kamioka, Naoto Yamamoto, Satoshi Kobayashi, Makoto Ueno, Manabu Morimoto, Sho Sawazaki, Hiroshi Tamagawa and 4 more

Open access · goldAbstract read
In one paragraph

Article in World journal of surgical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Masaaki MurakawaDepartment of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama City, 241-8515, Japan. m.murakawa@kcch.jp.
Shinnosuke KawaharaDepartment of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama City, 241-8515, Japan.
Daishi TakahashiDepartment of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama City, 241-8515, Japan.
Yuto KamiokaDepartment of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama City, 241-8515, Japan.
Naoto YamamotoDepartment of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama City, 241-8515, Japan.
Satoshi KobayashiDepartment of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan.
Makoto UenoDepartment of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan.
Manabu MorimotoDepartment of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan.
Sho SawazakiDepartment of Surgery, Yokohama City University School of Medicine, Yokohama, Japan.
Hiroshi TamagawaDepartment of Surgery, Yokohama City University School of Medicine, Yokohama, Japan.
Takashi OhshimaDepartment of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama City, 241-8515, Japan.
Norio YukawaDepartment of Surgery, Yokohama City University School of Medicine, Yokohama, Japan.
Yasushi RinoDepartment of Surgery, Yokohama City University School of Medicine, Yokohama, Japan.
Soichiro MorinagaDepartment of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama City, 241-8515, Japan.
Kanagawa Prefectural Hospital Organization · JPYokohama City University · JPKanagawa Cancer Center

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers, and surgical resection is the only potentially curative approach. However, the rate of recurrence remains high, particularly within the first 6 months, and is associated with a poor prognosis. The present study evaluated the clinical characteristics and risk factors for early recurrence in pancreatic ductal adenocarcinoma (PDAC) patients who underwent curative resection, regardless of the use of neoadjuvant chemotherapy, to identify predictive factors associated with early recurrence and poor outcomes as well as to determine the optimal treatment strategy for patients at high risk of early recurrence after surgical resection.

methodsPatients who underwent pancreatic resection for PDAC at our institution from 2013 to 2021 were included in this study. We investigated the clinicopathological features of patients in groups: those with recurrence within 6 months, recurrence between 6 and 12 months, and recurrence beyond 12 months or no recurrence. A logistic regression analysis identified covariates associated with early recurrence at 6 and 12 months.

resultsThe study included 403 patients with a median follow-up of 25.7 months. Recurrence was observed in 279 patients, with 14.6% recurring within 6 months, 23.3% within 6-12 months, and 62% after 12 months or not at all. The preoperative CA19-9 level, modified Glasgow prognostic score (mGPS), and positive peritoneal cytology were significant risk factors for early recurrence within 6 months, while positive peritoneal cytology, lymph node metastasis, and the absence of adjuvant chemotherapy were significant risk factors for recurrence within 12 months. For patients who received preoperative chemotherapy or chemoradiotherapy, the preoperative CA19-9 level, mGPS, and positive peritoneal cytology were significant independent risk factors for early recurrence within 6 months, while positive peritoneal cytology, lymph node metastasis, and the absence of adjuvant chemotherapy were significant independent risk factors for recurrence within 12 months. The study concluded that the overall survival after surgical resection for potentially resectable PDAC worsened according to the number of risk factors present in the patient.

conclusionsWe clarified that preoperative CA19-9, positive peritoneal cytology, and the lack of adjuvant chemotherapy were consistent predictors for early recurrence within 6 and 12 months. In addition, an increased number of risk factors affecting the patient was associated with a poorer overall survival after potentially curable resection. Calculating the number of risk factors for early recurrence may be an essential predictive factor when considering treatment strategies.

Indexed as

AdenocarcinomaCarcinoma, Pancreatic DuctalPancreatic NeoplasmsCA-19-9 AntigenHumansLymphatic MetastasisRisk FactorsCA-19-9 AntigenEarly recurrenceNeoadjuvant therapyPancreatic ductal adenocarcinomaRisk factors

Identifiers

PMID37620940
PMCPMC10463749
OpenAlexW4386120984

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.